Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Intensive lifestyle interventions slow multimorbidity gains in the long run in elderly adults

31 Jul 2020

Multidomain intensive lifestyle interventions (ILIs) may decelerate the accumulation of multimorbidity over time in overweight or obese elderly adults with type 2 diabetes, a recent study has shown.

Researchers performed a randomized controlled clinical trial on 5,145 volunteers (aged 45–76 years) with type 2 diabetes mellitus who were overweight or obese. The outcome was a multimorbidity index, which included conditions such as cancer, chronic kidney disease, congestive heart failure, hypertension, and stroke, among others. All-cause death was also included as an outcome component.

Interventions were ILI (n=2,570) and diabetes support and education (DSE; n=2,575). By the 8-year follow-up, multimorbidity scores had increased in both treatment arms, though the magnitude was greater in the DSE group (0.98 vs 0.89; p=0.003). Furthermore, multimorbidity scores increased in 63.3 percent of the DSE group, as opposed to only 59.6 percent of the ILI patients.

ILI showed relative superiority to DSE in terms of most components of the multimorbidity score. Most prominently, ILI yielded better results for chronic kidney disease (p=0.04) and hypertension (p=0.005). Cardiac arrhythmia and cancer scores were found to have greater increases in the ILI group, but the changes were not statistically significant.

Removing all-cause death from the composite had minimal effect on the principal outcome. ILI continued to yield lower 8-year increases in the multimorbidity index scores than DSE (mean difference, 0.08, 95 percent confidence interval, 0.02–0.13; p=0.006).

The researchers saw no significant subgroup effect on the effect of ILI vs DSE on multimorbidity scores according to baseline demographics.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.